Asthma (Severe), Add-on maintenance therapy

Monoclonal Antibody, Anti-Asthmatic
Tezepelumab-ekko is a human monoclonal antibody that binds to human thymic stromal lymphopoietin (TSLP), an epithelial cytokine, and prevents human TSLP from interacting with the heterodimeric TSLP receptor. Blocking TSLP with tezepelumab-ekko reduces biomarkers and cytokines associated with inflammation.

1.Distribution: Vd : 3.9 L (central); 2.2 L (peripheral).
2.Metabolism: Undergoes proteolytic degradation via enzymes that are widely distributed in the body; not metabolized by hepatic enzymes.
3.Bioavailability: ~77%.
4.Half-life elimination: ~26 days.

Hypersensitivity to tezepelumab or any component of the formulation.

Fetal risk cannot be ruled out.
Available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.

Infant risk cannot be ruled out.

1.Immunologic: Antibody development
2.Neuromuscular & skeletal: Arthralgia , back pain
3.Respiratory: Pharyngitis

Asthma, severe: SUBQ: 210 mg once every 4 weeks. A minimum of 4 months of treatment is suggested to determine efficacy.
May consider as add-on therapy in patients with severe asthma (with or without inflammatory markers) and a history of severe exacerbations .

Asthma, severe; maintenance therapy
Children 12 years and Adolescents: SUBQ: 210 mg every 4 weeks.